Charles River Laboratories International, Inc. $CRL Stock Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. trimmed its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 44.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,121 shares of the medical research company’s stock after selling 8,149 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Charles River Laboratories International were worth $2,986,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Lido Advisors LLC bought a new stake in Charles River Laboratories International in the 3rd quarter valued at $1,205,000. New York Life Investment Management LLC lifted its stake in Charles River Laboratories International by 371.3% in the 3rd quarter. New York Life Investment Management LLC now owns 61,506 shares of the medical research company’s stock worth $18,145,000 after purchasing an additional 48,455 shares in the last quarter. AlphaCore Capital LLC boosted its holdings in shares of Charles River Laboratories International by 222.4% during the 3rd quarter. AlphaCore Capital LLC now owns 5,184 shares of the medical research company’s stock valued at $1,529,000 after purchasing an additional 3,576 shares during the last quarter. Retirement Systems of Alabama boosted its holdings in shares of Charles River Laboratories International by 1,246.1% during the 3rd quarter. Retirement Systems of Alabama now owns 136,211 shares of the medical research company’s stock valued at $40,184,000 after purchasing an additional 126,092 shares during the last quarter. Finally, Fulcrum Asset Management LLP bought a new position in shares of Charles River Laboratories International during the 3rd quarter valued at about $85,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Shannon M. Parisotto sold 2,156 shares of the firm’s stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total value of $742,547.96. Following the completion of the sale, the executive vice president directly owned 4,807 shares of the company’s stock, valued at $1,655,578.87. This trade represents a 30.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James Foster sold 33,561 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total value of $10,068,300.00. Following the completion of the sale, the director directly owned 31,596 shares of the company’s stock, valued at $9,478,800. The trade was a 51.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 63,352 shares of company stock worth $20,291,281. Corporate insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Barclays lifted their target price on Charles River Laboratories International from $330.00 to $375.00 and gave the stock an “overweight” rating in a report on Thursday, November 5th. UBS Group increased their price target on Charles River Laboratories International from $357.00 to $387.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Argus set a $330.00 price target on Charles River Laboratories International in a report on Thursday, September 17th. Zacks Research downgraded Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 2nd. Finally, TD Cowen reaffirmed a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday. Thirteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $308.17.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL opened at $341.12 on Friday. Charles River Laboratories International, Inc. has a 52 week low of $146.20 and a 52 week high of $379.63. The stock has a market capitalization of $16.35 billion, a P/E ratio of 374.86, a PEG ratio of 3.10 and a beta of 1.36. The firm has a fifty day simple moving average of $310.31 and a two-hundred day simple moving average of $227.65. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.76.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, topping analysts’ consensus estimates of $2.97 by $0.12. The firm had revenue of $982.73 million for the quarter, compared to the consensus estimate of $960.36 million. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. The business’s quarterly revenue was down 2.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.43 EPS. On average, analysts expect that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.